{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:42:59Z","timestamp":1774410179411,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["The study was funded by Eli Lilly and Company"],"award-info":[{"award-number":["The study was funded by Eli Lilly and Company"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40744-021-00388-8","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T08:02:52Z","timestamp":1635408172000},"page":"109-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Na\u00efve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H"],"prefix":"10.1007","volume":"9","author":[{"given":"Lars-Erik","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyi Liu","family":"Leage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"El Baou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P.","family":"Dutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"issue":"3","key":"388_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","volume":"55","author":"A McArdle","year":"2018","unstructured":"McArdle A, Pennington S, FitzGerald O. Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs. Clin Rev Allergy Immunol. 2018;55(3):271\u201394.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"388_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/2475530319890832","volume":"5","author":"R Holland","year":"2020","unstructured":"Holland R, H\u00f8jgaard P, Tillett W, et al. Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as core instrument to measure health-related quality of life in psoriatic arthritis: a systematic review of psychometric properties. J Psoriasis Psoriatic Arthritis. 2020;5(1):12\u201322.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"9","key":"388_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"388_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","volume":"7","author":"W Tillett","year":"2020","unstructured":"Tillett W, Merola JF, Tha\u00e7i D, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7(3):617\u201337. https:\/\/doi.org\/10.1007\/s40744-020-00221-8.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"388_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"388_CR6","unstructured":"European Medicines Agency. Ixekizumab (Taltz): summary of product characteristics 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf. Accessed 29 July 2020."},{"issue":"1","key":"388_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Smolen J, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"388_CR8","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313.","journal-title":"J Immunol"},{"issue":"10","key":"388_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020;79(10):1310\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217372.","journal-title":"Ann Rheum Dis"},{"key":"388_CR10","unstructured":"European Medicines Agency. Adalimumab (Humira): summary of product characteristics 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf. Accessed 29 July 2020."},{"key":"388_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05891-5","author":"F Behrens","year":"2021","unstructured":"Behrens F, Liu Leage S, Sapin C, et al. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. Clin Rheumatol. 2021. https:\/\/doi.org\/10.1007\/s10067-021-05891-5 ((Epub ahead of print)).","journal-title":"Clin Rheumatol"},{"issue":"Suppl 1","key":"388_CR12","doi-asserted-by":"publisher","first-page":"i21","DOI":"10.1093\/rheumatology\/keaa042","volume":"59","author":"P Mease","year":"2020","unstructured":"Mease P. Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management. Rheumatology (Oxford). 2020;59(Suppl 1):i21\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"388_CR13","doi-asserted-by":"publisher","first-page":"e001223","DOI":"10.1136\/rmdopen-2020-001223","volume":"6","author":"G Haugeberg","year":"2020","unstructured":"Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020;6(1):e001223.","journal-title":"RMD Open"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00388-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T12:46:28Z","timestamp":1643892388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00388-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00388-8","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company, Indianapolis, IN, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors would like to acknowledge Dr. Elinor Wylde and Dr. Sue Chambers (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript, funded by Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"Lars-Erik Kristensen made substantial contributions to the acquisition and interpretation of data, and critical revision of the manuscript. Masato Okada made substantial contributions to the interpretation of data and critical revision of the manuscript. William Tillett made substantial contributions to the interpretation of data and critical revision of the manuscript. Soyi Liu Leage made substantial contributions to conception and design of the work, the analysis and interpretation of data, and drafting and critical revision of the manuscript. Celine El Baou made substantial contributions to the design of the work, the analysis and interpretation of data, and critical revision of the manuscript. Christophe Sapin made substantial contributions to the design of the work, the analysis and interpretation of data, and critical revision of the manuscript. Andrew Bradley made substantial contributions to the analysis and interpretation of data, and critical revision of the manuscript. Gabriella Meszaros made substantial contributions to conception and design of the work, the analysis and interpretation of data, and drafting and critical revision of the manuscript. Jan Dutz made substantial contributions to the interpretation of data and critical revision of the manuscript. Kurt de Vlam made substantial contributions to the acquisition and interpretation of data, and critical revision of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The authors would like to acknowledge the investigators and participants in the SPIRIT-H2H study. The SPIRIT-H2H investigators were: Leonardo Naftal, Rodolfo Ariel Pardo Hidalgo, Eduardo Mario Kerzberg, Veronica Gabriela Savio, Alicia Lazaro, Benito Jorge Velasco, Norma Beatriz Verzero, Cecilia Adma Asnal, Eduardo Fabian Mysler, Alberto Berman, Federico Javier Ariel, Maureen Rischmueller, Jane Margaret Zochling, Paul A Bird, Stephen Hall, Andrew Ostor, Evange Romas, Georg Stummvoll, Klaus Machold, Peter Spellitz, Ursula Hanusch, Marc Vanden Berghe, Marc Leon, Johan Louis Magda Vanhoof, Filip Eduard Jeanne Van den Bosch, Kurt Leo Francois De Vlam, Frederic Morin, Louis Bessette, Derek A Haaland, Annette Margrethe Schlemmer, Lars Erik Kristensen, Pentti Jarvinen, Ritva Liisa Peltomaa, Laura Pirila, Jorma Vuotila, Eric Lespessailles, Philippe Goupille, Bernard Combe, Arnaud Constantin, Gregoire Cormier, Celine Cozic, Cyrille B Confavreux, Hendrik Schulze-Koops, Andrea Everding, Micheala Kohm, Siegfried Wassenberg, Magdolna Nagy, Noemi Bakos, Eva Melegh, Edit Drescher, Lalit Duggal, Piyush Narayanbhai Joshi, Srabani Ghosh Zoha, A Ramakrishnam Naidu, Puja Pushkarkumar Srivastava, Vishnu Devkinandan Sharma, Ajit Bapurao Nalawadae, Jyotsna Laxmikant Oak, Sarath Chandra Mouli Veeravalli, Jugal Kishore Kadel, Manisha Ashwin Daware, Yogesh S Marfatia, Sumeet Agarwal, Yolanda Braun Moscovici, Ori Elkayam, Yair Molad, Tatiana Reitblat, Moshe Tishler, Yair Levy, Merav Lidar, Devy Zisman, Antonio Costanzo, Paolo Amerio, Riccardo Meliconi, Rosario Foti, Roberto Perricone, Maurizio Rossini, Elisa Gremese, Beatriz Elena Zazueta Montiel, Juan Manuel Miranda Limon, Marco Antonio Maradiaga Cecena, Sandra Araceli Sicsik Ayala, Miguel Angel Alvarez Guerrero, Jorge Rojas Serrano, Efren Antonio Canul Novelo, Francisco Fidencio Cons-Molina, Ed N Griep, Andrzej Kaszuba, Jolanta Bogna W\u0119g\u0142owska, Barbara Bazela, Maria Rell-Bakalarska, Malgorzata Miakisz, Catherine Elizabeth Spargo, Elsa Margaretha Van Duuren, Asokan Naidoo, Nomawethu Cleopatra Matsiliza, Johannes Breedt, Gareth Scott Tarr, Jenny Potts, Savithree Nayiager, Mahmood Moosa Tar Mahomed Ally, Francisco Javier Blanco Garcia, Antonio Mera Varela, Jose Rosas, Juan Miguel Sanchez Burson, Javier Garcia Miguel, Jon Lampa, Milad Rizk, Giovanni Cagnotto, Per Larsson, Guozhong Fei, Ruediger Mueller-Mar, Andrea Rubbert-Roth, Michael John Nissen, Oleh Iaremenko, Svitlana Anatoliivna Trypilka, Dmytro Rekalov, Mykola Stanislavchuk, Viktoriia Viktorivna Vasylets, Olena Garmish, Svitlana Smiyan, David Walker, Deepak Jadon, Stuart Ralston, Stephen Boyle, Pippa Anne Watson, James E Dale, Sara Carty, Karen Douglas, Christopher J Edwards, David Hutchinson, and Nick Barkham.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"List of Investigators"}},{"value":"This manuscript is based on work that has been previously published [, ] and on an abstract presented on 8 November at ACR Convergence 2020 (virtual meeting): Kristensen L, et al. Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PsA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomised open-label study [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10). .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentation"}},{"value":"LEK has received consultancy fees and speaker\u2019s bureau fees from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen Pharmaceuticals, Merck, Sharp & Dohme (MSD), Novartis, Pfizer, Roche, Sanofi, and UCB Pharma (unrelated to the present work). MO and KdV have nothing to disclose. SLL, CS, AB and GM are employees and stockholders of Eli Lilly and Company. CEB is an independent consultant contracted by Eli Lilly and Company. WT has received research grants, consulting fees or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly and Company, Janssen, MSD, Novartis, Pfizer and UCB. JD has performed clinical trials for Corbus, Eli Lilly and Company and Janssen; has received honoraria from AbbVie, Amgen, Bausch, Celgene, Leo, Janssen, Novartis and Sanofi; and has worked on the speaker bureau for Celgene and Eli Lilly and Company.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"SPIRIT-H2H was conducted in accordance with the ethical principles of the Helsinki Declaration of 1964 and its later amendments. All patients involved provided written informed consent, and the study protocol was approved by the ethical review board of each investigative site (Supplementary Table S3) and the National Research Ethics Service Committee London (17\/LO\/0794) prior to the start of study-related procedures. SPIRIT-H2H is registered at ClinicalTrials.gov (NCT03151551).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at .","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}